Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model
© Dai et al.; licensee BioMed Central Ltd. 2012
Received: 2 April 2012
Accepted: 16 October 2012
Published: 21 November 2012
The effects of Hepatitis B virus (HBV) rtA181T/sW172* mutation on viral replication and pathogenicity was concerned recently. This study aimed to investigate the biological characteristics of rtA181T/sW172* mutant strain of HBV in animal model.
The rtA181T/sW172* mutant plasmid was constructed using the pHBV4.1 (wild type HBV) as a template. The wild and mutant HBV replication mouse models were established utilizing a hydrodynamic technique. The titers of hepatitis B surface antigen (HBsAg), hepatitis B e antigen, and HBV DNA in serum, and the levels of HBsAg, hepatitis B core antigen(HBcAg), HBV DNA replication intermediates (HBV DNA RI) and HBV RNA in liver were measured after 1, 3, 5, 7, 10, 12 and 15 days of plasmid injection.
In wild-type HBV replication mouse model, serum HBsAg was high on day 1, 3, and 5, but became lower since day 7; while in mutant HBV mouse model, serum HBsAg was always at very low level. In liver tissues, HBV DNA RI of wild type HBV was detected on day 1 after transfection. The level subsequently peaked on day 3, gradually declined after day 5, and was almost undetectable on day 10. However, the HBV DNA RI levels of the mutant strain were always higher and lasted longer until day 15. Consistently, the expression levels of HBsAg and HBcAg in liver of the mutant group were significantly increased.
In the case of the HBV rtA181T/sW172* mutation, the secretion of serum HBsAg was impaired, whereas HBV DNA replication and HBsAg/HBcAg expression were increased in liver. These results suggest that the mutation can impair HBsAg secretion, and may cause the accumulation of viral core particles in liver.
KeywordsHepatitis B virus rtA181T/sW172* mutation Transcription and replication Hepatitis B surface antigen Secretion defect Drug sensitivity
More than 350 million people are chronically infected with HBV worldwide, which leads to about 1 million death per year. There are currently two classes of antiviral agents for chronic hepatitis B (CHB): nucleos(t)ide analogs (NAs) directly inhibiting HBV DNA replication and interferon-based therapies that may modulate the host immune response as well as viral replication. However, widespread use of NAs in the clinics might have contributed to the increased incidence of drug resistant cases.
HBV, a member of the hepadnavirus family, is an enveloped virus that contains a partially-double stranded circular DNA about 3.2 kb in length. HBV DNA has a very compact coding organization with four partially overlapping open reading frames (ORFs), including ORF P, X, S and C. Among them, ORF P that encodes the RT (reverse transcriptase) domains of the polymerase overlaps completely with the ORF S that encodes HBV surface proteins. The HBV surface proteins, including the S protein (226 amino acids), the M protein (281 amino acids), and the L protein (389–400 amino acids), are encoded by one long open reading frame that utilizes three different start codons and the same stop codon. The major functions of the HBV surface proteins include envelopment of nucleocapsid with subsequent assembly of virion, and assembly into empty subviral particles that are secreted in great excess over HBV virions collectively referred to as hepatitis B surface antigen. The surface proteins also are targets of the host cellular immune system. The extent to which the host recognizes viral antigens presented by infected cells determines whether an infection will be acute or chronic.
The HBV rtA181T/sW172* mutant strain researched in this study is that the rtA181T mutation in the viral polymerase encodes a stop codon in the overlapping surface gene at amino acid 172 (sW172) resulting in truncation of the last 55 amino acids of the C-terminal hydrophobic region of the surface proteins. The rtA181T mutation causes drug resistance to adefovir (ADV) clinically. It has been revealed in cell culture that the mutation results in a decreased susceptibility to lamivudine (LAM), ADV, and tenofovir, while remaining sensitive to entecavir (ETV). The rtA181T/sW172* mutation also reduces the typical extent of virological breakthrough. Previous studies in vitro also demonstrated that the rtA181T/sW172* mutation may impair HBsAg secretion, and may be an oncogenic potential factor leading to advanced hepatocellular carcinoma (HCC). However, the effect of the rtA181T/sW172* mutation on HBV virology in vivo remains unclear. So it is thus necessary to study the biological characteristics of the HBV rtA181T/sW172* mutation in vivo environment.
In this study, a mouse model for the replication of the HBV rtA181T/sW172* mutant was established using a hydrodynamic-based procedure. The effect of the rtA181T/sW172* mutation on HBV transcription, replication and HBsAg secretion were investigated.
Expression levels of HBsAg and HBeAg in mouse serum
HBV-DNA level in mouse serum
Compared to wild type, the rtA181T/sW172* mutant strain showed an approximately 0.8 log reduction on day 1, 2.6 log reduction on day 3, 1.5 log reduction on day 5, and 0.7 log reduction on day 7 in serum HBV DNA titers. The serum HBV DNA levels of the mutant strain were always lower than that of wild type. The difference was significant on day 1, 3, 5 and 7, respectively (Figure 1C). Since day 10, viral loads decreased to very low level for both two groups.
HBV RNA transcription level in mouse liver
Levels of HBV DNA replication intermediates in mouse liver
Expression levels of HBsAg and HBcAg in mouse liver
Inhibition effects of antiviral drugs on wild type and mutant HBV in vivo
Materials and methods
This study obtained ethics approval from the Laboratory Animal ethics committee of Sichuan University.
The wild type pHBV4.1 (pHBVwt [wt, wild-type]) is an HBV replication competent plasmid which contains 1.3 copies of the HBV genome (subtype ayw) and is capable of HBV transcription, replication, and expression both in vitro and in vivo. A point mutation (rtA181T) in the RT region replacing Alanine (A) 181 with Threonine (T) was introduced via site-directed mutagenesis (QuikChange mutagenesis kit, Stratagene) according to the manufacturer’s instructions using the forward primer: 5'-CAGCCCGTTTCTCCTGACTCAGTTTACTAGTGC-3' and the reverse primer: 5'-GCACTAGTAAACTGAGTCAGGAGAAACGGGCTG-3'. The resulting mutant plasmid was named pHBVmut (mut, mutation type). This mutation also created a premature stop codon that replaces amino acid 172W of HBsAg.
A mouse model for HBV replication
Male BALB/C mice that were maintained in specific-pathogen-free (SPF) conditions and weighted 18-20g were purchased from the Laboratory Animal Center at Sichuan University. All mice received humane care under the Institutional Review Board in accordance with Animal Protection Art of Sichuan University.
In order to establish the mouse model for HBV replication, 10μg of pHBV4.1 or pHBVmut plasmids diluted in phosphate-buffered saline (PBS) was injected into the mouse tail vein in a volume of 10% of the body weight (v/w) within 5–8 seconds (hydrodynamic in vivo transfection). Mice were sacrificed after 1, 3, 5, 7, 10, 12 and 15 days of DNA injection. Liver tissues and blood were collected.
HBV antigen assays
Serum HBsAg and HBeAg were measured using ELISA kits following the manufacturer’s protocol (Shanghai Shiye Kehua Company, China). Absorbance was measured in a microtiter plate reader with dual-wave length measurement (450/645nm).
Formalin-fixed liver tissues from the treated mice were embedded in paraffin. HBsAg and HBcAg were detected by immunohistochemical staining using specific antibodies against HBsAg (mouse anti-HBs, Thermol) and HBcAg (rabbit anti-HBc, NEOMARKERS), respectively. All procedures for the immunological detections of these antigens were performed according to the manufacturer's protocol.
Analysis of liver HBV RNA
Mouse liver tissues were mechanically pulverized in liquid nitrogen, and total RNA was extracted from pulverized tissues using Trizol reagent following the manufacturer’s instructions (Invitrogen, USA). The 30 μg HBV RNA was analyzed by Northern blotting hybridization using probes for both GAPDH and HBV, with the GAPDH serving as an internal control.
Analysis of liver HBV DNA replication intermediates
Frozen liver tissues were mechanically pulverized in liquid nitrogen and HBV DNA replication intermediates were isolated from one hundred and twenty micrograms of liver tissue powder as described previously. And these HBV DNA replication intermediates were diluted to 30 μl with TE buffer. All of viral replication intermediates was analyzed by Southern blotting as previously described. Membranes were hybridized with digoxigenin-labeled (Roche Applied Science) HBV ayw genomic DNA to detect HBV sequences. The levels of HBV DNA replication intermediates were calculated by the Quantity One software according to manufacturer’s instructions (Bio-Rad).
Detection of HBV-DNA and HBV-RNA by quantitative real-time PCR
100 μL of mice serum predigested with DNaseIwas used for the detection of HBV DNA by quantitative real-time PCR (qPCR) using a diagnostic kit for quantification of HBV-DNA (Da An Gene, Guangzhou, China).
The qPCR analysis of HBV RNA in mice liver was performed using the LightCycler system (Bio-Rad). Amplification was carried out in two steps: denaturation at 95°C for 5 sec and annealing at 60°C for 5 sec. Also the number of PCR cycles was 30 times. To distinguish specific from nonspecific cDNA products, a melting curve was obtained at the end of each run. Data were normalized against the GAPDH level in each sample. HBV RNA was detected using the C region primer pairs (forward: 5'-CTGGGTGGGTGTTAATTTGG-3', reverse: 5'-TAAGCTGGAGGAGTGCGA AT-3') and the S region primer pairs (forward: 5'-CTCCAATCACTCACCAACCT-3', reverse: 5'-TCCAGA AGA ACCAACAAG AAG A-3'). The primers for GAPDH (internal control) were: forward: 5'-AACTTTGGCATTGTGGAAGG-3', reverse: 5'-ACACATTGGGGGTAGGAACA-3'. (All primers were synthesized by Invitrogen, Shanghai, China).
Antiviral treatment utilizing NAs
Twenty-four hours after hydrodynamic injection, nucleoside analogues, including lamivudine (GlaxoSmithKline, 250mg/kg/d), adefovir (GlaxoSmithKline, 15mg/kg/d), entecavir (Bristol-Myers Squibb, 0.075mg/kg/d), and telbivudine (LdT, NOVARTIS, 1800mg/kg/d), and normal saline (NS) were administrated via oral gavage to mice injected with either the wild type or the mutant HBV for three times at 24-h intervals. The drug dose was determined based on the human body dosage and experimental experience. Mice were sacrificed 4–6 h after the final administration via oral gavage. Liver tissues were frozen in liquid nitrogen and stored at −70°C for DNA extraction and analysis.
CHB is one of the most common human infectious diseases worldwide. Infected individuals are at a high risk of developing liver cirrhosis and HCC. Treatment of CHB is aimed at suppressing HBV replication, at reducing the accompanying histological inflammation, and at decreasing the risk of cirrhosis and HCC. Therefore, antiviral therapies with NAs or interferon are currently the key treatments for CHB.
However, drug resistance is the major challenge associated with long-term therapy with NAs. Drug resistant HBV mutant strains will gradually become dominant, which leads to disease deterioration and other serious consequences. Many studies showed that treatment of CHB patients with LAM, ADV, or LdT could result in the emergence of the HBV rtA181T mutant[5, 16–18]. Clinically rtA181T is a common resistance mutation to ADV. This mutation not only induces a decreased susceptibility to ADV, LAM, and tenofovir, but also encodes S gene mutation. It is reported that the nonsence mutation at position 172 in the S gene leads to a 55 amino acids truncation of HBsAg. This mutation is therefore also called HBV rtA181T/sW172*, which may affect the biological characteristics and pathogenesis of HBV. However, the biological features of this HBV mutant in vivo still remain unclear.
Most of recent studies on HBV mutant were done in cultured cells. Transgenic mice[19, 20] are useful models to study HBV. However, establishing specific transgenic mice is time and cost consuming. The HBV replication mouse model that we established with a hydrodynamic-based procedure is a rapid and convenient alternative, especially for the characterization of HBV mutations. We have constructed the rtA181T/sW172* mutant strain of HBV and investigated its biological characteristics in vivo with our HBV replication mouse model.
Firstly, we found that serum HBsAg level of the rtA181T/sW172* mutant was very low (OD<0.4) from day 1 to day 15 after in vivo transfection (Figure 1A), and that the serum HBV DNA level of the mutant was lower than that of wild type (Figure 1C). This may be explained by the fact that the rtA181T/sW172* mutation causing the production of truncated HBsAg, which cannot be secreted into the serum. HBsAg plays an important role in the packaging and secretion of virion. The complete HBV virion consists of an icosahedral nucleocapsid core and an outer lipid envelope, in which the three envelope proteins [small (S), medium (M) and large (L)] are anchored as transmembrane proteins playing a major role in HBV morphogenesis and infectivity. And the mature nucleocapsid enveloped by the surface proteins can be released to serum. As the S gene overlaps the P gene completely, the A→T mutation at position 181 of the P gene in the RT domain replaces the amino acid tryptophan 172 of the S gene with a termination codon, resulting in the truncation of the last 55 amino acids. All of the HBV surface proteins (S protein, M protein, L protein) decrease approximately 6 kDa in molecular weight. These truncated surface proteins may affect the virus assembly and secretion. In this study, the mostly HBV virions and HBsAg assembled by these truncated surface proteins may not be secreted into serum and thus became accumulated in liver. It seems that the function of the truncated 55 amino acids in the C-terminal is critical for HBV assembly. The rtA181T/sW172* mutation thus leads to defects in the assembly and secretion of HBsAg and virion, which results in decreased levels of serum HBsAg and HBV DNA.
Detection of HBsAg is achieved by antibody-based assays targeting the ‘a’ determinant, the highly homologous region within HBsAg, which is also used as the main target by hepatitis B vaccines. Recognition of the ‘a’ determinant by antibody against HBsAg (anti-HBs) depends on its 3D conformation, which also relies on the amino acid sequence of the regions flanking the ‘a’ determinant. However, mutants of HBsAg continue to evolve as a result of vaccine escape, immune selection, and an error prone reverse transcriptase. Because the sW172* mutation of HBsAg gene is not inside the ‘a’ determinant, currently commercially antibody for truncated HBsAg is effective. In addition, the immunohistochemistry results of HBsAg in liver tissue also supported the effectiveness of conventional antibody for truncated HBsAg detection. So the low serum HBsAg in mutant HBV mice model should be due to the intracelluar retention of truncated HBsAg. As detection of HBV DNA in serum is qPCR-based assays, the HBV DNA can be observed even if it is very little. Compared with the wild mice, the level of HBV DNA in mutant mice serum decreased significantly, and these finds were consistent with the conditions of patients who had the HBV rtA181T/sW172* mutation.
However, the synthesis and secretion of HBeAg, a secretory antigen, is regulated differently from HBsAg, and is regulated by HBV C open reading frame. Serum HBeAg of two groups showed similar patterns.
Secondly, our study revealed that the expression levels of HBsAg and HBcAg in liver of mice infected with the mutant HBV were higher than those of wild type, especially on day 5 and day 7 (Figure 3). HBsAg, the envelope protein, is normally secreted into serum following infection. HBcAg, the nucleocapsid protein, is synthesized in infected cells and is required for HBV viral replication. It seems that the mutant HBV has defects in the secretion of virions and HBsAg, leading to the accumulation of a large number of viral particles and HBsAg in liver.
The expression levels of HBV RNA and DNA of the mutant HBV were higher and lasted longer in liver than wild type (Figure 2,3), which may be due to the increased capability of mutant HBV transcription and replication . To classify this issue, it is necessary to study the promoter activity of the mutant HBV in the future research. As compared to wild type HBV strain, the transcription and replication levels of the HBV rtA181T/sW172* mutant strain in vivo delayed in reaching the peak level and lasted significantly longer, and the mutation also was demonstrated HBsAg and HBcAg continued retention in liver. And these antigens in the liver tissue may stimulate prolonged immune response. Previous evidences showed that the adaptive immune response should be responsible for viral clearance and disease pathogenesis during HBV infection. Though HBV is not directly hepatotoxic[27, 28], recent studies of HBV insertions in HBV-related HCCs revealed that HBV integration can target the telomerase reverse transcriptase gene, suggesting a potential role for viral insertion in HBV-related carcinogenesis[29–31]. The cytotoxic T lymphocyte (CTL) not only kills the virus, but also kills the infected hepatocyte, leading to liver damage. Persistent infection of HBV is characterized by chronic liver cell injury, regeneration, inflammation, widespread DNA damage, cirrhosis of the liver, and hepatocellular carcinoma. Further studies are ongoing to investigate where and why the secretion of the mutant HBsAg and HBV virions is impaired, and to explore the mechanism of mutant HBV accumulation in liver. The related research will be reported in the future.
Thirdly, cell culture studies have showed that the single amino acid substitution at position rt181 in HBV is the primary resistance mutation to ADV and it also causes cross resistance to LAM and LdT. The concentrations of LAM and LdT for 50% inhibition of HBV replication (IC50) are 0.023μM and 0.335μM, respectively. Our study found that the folds of decrease in the sensitivity of the mutant to LAM, ADV, and LdT are different. However, this study utilized 0.022 μM of LAM, 0.0051 μM of ETV and 0.15 μM of LdT in our mouse models. The corresponding concentration of LAM in human would be 16.67 times the normal oral dose, that of ETV would be equivalent to the normal dose, and that of LdT would have reached 20 times the normal dose. Oral ADV reduced HBV DNA in both serum and liver significantly better than LAM, and also worked well at concentrations as low as 1.0 mg/kg/day. So in this study, the antiviral effect to HBV rtA181T/sW172* is ETV>ADV>LAM>LdT. It is related to the establishment method of the mouse model, individual difference of mice and the drug concentration.
Currently most drug resistance monitoring in clinical practice is achieved by detecting viral load, not by direct sequencing. Serum viral load would not be as high as expected for the kind of variant. This makes us to focus on the HBV rtA181T/sW172* mutation. If the patient carries the variation and we failed to change drug in time, the disease would deteriorate, once rtA181T/sW172* become the dominant strains. However, the mouse model used in this study is a transient HBV infection model. The chronic influence of the mutant virus to mice requires further study.
In conclusion, our results indicated that the rtA181T/sW172* mutation might impair serum HBsAg secretion and reduce serum HBV DNA level. However, the transcription and replication levels of the mutant strain in liver tissues were increased, which may be explained by the accumulation of viral core particles in liver or the enhanced replication ability of this mutant strain. The clinical consequences of infection by these S gene mutants demand further clarification. Judicious selection of antiviral agents and vigilant monitoring of viral mutants during the course of therapy are advised.
Hepatitis B virus
Hepatitis B surface antigen
Hepatitis B e antigen
Hepatitis B core antigen
Chronic hepatitis B
- HBV DNA RI:
HBV DNA replication intermediates
Quantitative real-time PCR
This study was supported by grants from the National Natural Science Foundation of China (No. 81071363), National Science and Technology Major Project of China (No. 2012ZX10002007 and No. 2008ZX10002-006), 973 Program of China (No. 2007CB512902), and National S&T Major Project for Infectious Diseases Control (2009ZX10004-905). We are grateful to Alan McLachlan (The Scripps Research Institute, La Jolla, CA, USA) for plasmid pHBV4.1. We also thank the following people for their help and support in this experiment: Ms. Cong Liu, Ms. Li Liu, Dr. Tao-You Zhou, and Dr. Fang He.
- Lupberger J, Hildt E: Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007, 13: 74-81.PubMedPubMed CentralView ArticleGoogle Scholar
- Bartholomeusz A, Locarnini S: Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006,78(Suppl 1):S52-S55.PubMedView ArticleGoogle Scholar
- Michel ML, Tiollais P: Structure and expression of the hepatitis B virus genome. Hepatology 1987, 7: 61S-63S. 10.1002/hep.1840070711PubMedView ArticleGoogle Scholar
- Warner N, Locarnini S: The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008, 48: 88-98. 10.1002/hep.22295PubMedView ArticleGoogle Scholar
- Kim JH, Jung YK, Joo MK, Yim HJ, Park JJ, Kim JS, Bak YT, Yeon JE, Byun KS: Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. J Korean Med Sci 2010, 25: 257-264. 10.3346/jkms.2010.25.2.257PubMedPubMed CentralView ArticleGoogle Scholar
- Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F: Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008, 48: 747-755. 10.1016/j.jhep.2008.01.027PubMedView ArticleGoogle Scholar
- Lai MW, Yeh CT: The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008, 13: 875-879.PubMedGoogle Scholar
- Liu FJ, Liu L, He F, Wang S, Zhou TY, Liu C, Deng LY, Tang H: Establishment and primary application of a mouse model with hepatitis B virus replication. World J Gastroenterol 2007, 13: 5324-5330.PubMedPubMed CentralView ArticleGoogle Scholar
- Tang H, McLachlan A: Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci USA 2001, 98: 1841-1846. 10.1073/pnas.98.4.1841PubMedPubMed CentralView ArticleGoogle Scholar
- Tang H, McLachlan A: A pregenomic RNA sequence adjacent to DR1 and complementary to epsilon influences hepatitis B virus replication efficiency. Virology 2002, 303: 199-210. 10.1006/viro.2002.1645PubMedView ArticleGoogle Scholar
- Liu F, Song Y, Liu D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999, 6: 1258-1266. 10.1038/sj.gt.3300947PubMedView ArticleGoogle Scholar
- Tang H, Delgermaa L, Huang F, Oishi N, Liu L, He F, Zhao L, Murakami S: The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J Virol 2005, 79: 5548-5556. 10.1128/JVI.79.9.5548-5556.2005PubMedPubMed CentralView ArticleGoogle Scholar
- Gao Z, Liu FJ, Liu L, Zhou TY, Lei J, Xu L, Liu C, Dai J, Chen EQ, Tang H: Application of hepatitis B virus replication mouse model. World J Gastroenterol 2010, 16: 1979-1985. 10.3748/wjg.v16.i16.1979PubMedPubMed CentralView ArticleGoogle Scholar
- Lee WM: Hepatitis B virus infection. N Engl J Med 1997, 337: 1733-1745. 10.1056/NEJM199712113372406PubMedView ArticleGoogle Scholar
- EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009, 50: 227-242. 10.1016/j.jhep.2008.10.001View ArticleGoogle Scholar
- Chien RN, Yeh CT, Wang PN, Kuo MC, Hsieh SY, Shih LY, Liaw YF: Acute leukaemia in chronic hepatitis B patients with lamivudine therapy. Int J Clin Pract 2004, 58: 1088-1091. 10.1111/j.1742-1241.2004.00266.xPubMedView ArticleGoogle Scholar
- Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, et al.: Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006, 50: 3867-3874. 10.1128/AAC.00239-06PubMedPubMed CentralView ArticleGoogle Scholar
- Yeh CT, Chien RN, Chu CM, Liaw YF: Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000, 31: 1318-1326. 10.1053/jhep.2000.7296PubMedView ArticleGoogle Scholar
- Schorr O, Borel C, Trepo C, Zoulim F, Hantz O: Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes. J Hepatol 2006, 44: 842-847. 10.1016/j.jhep.2005.09.014PubMedView ArticleGoogle Scholar
- Schinazi RF, Ilan E, Black PL, Yao X, Dagan S: Cell-based and animal models for hepatitis B and C viruses. Antivir Chem Chemother 1999, 10: 99-114.PubMedView ArticleGoogle Scholar
- Lentz TB, Loeb DD: Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus. J Virol 2011, 85: 11916-11927. 10.1128/JVI.05373-11PubMedPubMed CentralView ArticleGoogle Scholar
- Bruss V: Hepatitis B virus morphogenesis. World J Gastroenterol 2007, 13: 65-73.PubMedPubMed CentralView ArticleGoogle Scholar
- Weber B: Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol 2006,78(Suppl 1):S59-S65.PubMedView ArticleGoogle Scholar
- Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC: Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990, 336: 325-329. 10.1016/0140-6736(90)91874-APubMedView ArticleGoogle Scholar
- Lou SC, Pearce SK, Lukaszewska TX, Taylor RE, Williams GT, Leary TP: An improved Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg). J Clin Virol 2011, 51: 59-63. 10.1016/j.jcv.2011.01.019PubMedView ArticleGoogle Scholar
- Chisari FV, Isogawa M, Wieland SF: Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010, 58: 258-266. 10.1016/j.patbio.2009.11.001View ArticleGoogle Scholar
- Chisari FV: Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000, 156: 1117-1132. 10.1016/S0002-9440(10)64980-2PubMedPubMed CentralView ArticleGoogle Scholar
- Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006, 1: 23-61. 10.1146/annurev.pathol.1.110304.100230PubMedView ArticleGoogle Scholar
- Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, Lagorce D, Brechot C: Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003, 22: 3911-3916. 10.1038/sj.onc.1206492PubMedView ArticleGoogle Scholar
- Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Brechot C, Paterlini-Brechot P: Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005, 54: 1162-1168. 10.1136/gut.2004.054452PubMedPubMed CentralView ArticleGoogle Scholar
- Tamori A, Yamanishi Y, Kawashima S, Kanehisa M, Enomoto M, Tanaka H, Kubo S, Shiomi S, Nishiguchi S: Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin Canc Res 2005, 11: 5821-5826. 10.1158/1078-0432.CCR-04-2055View ArticleGoogle Scholar
- Chisari FV, Ferrari C: Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13: 29-60. 10.1146/annurev.iy.13.040195.000333PubMedView ArticleGoogle Scholar
- Locarnini S: Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008, 2: 147-151. 10.1007/s12072-008-9048-3PubMedPubMed CentralView ArticleGoogle Scholar
- Julander JG, Sidwell RW, Morrey JD: Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res 2002, 55: 27-40. 10.1016/S0166-3542(01)00223-6PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.